Lung Cancer Clinical Trials

G1T28-02

G1T28 (CDK 4/6 inhibitor) in combination with Etoposide and Carboplatin in extensive stage small cell lung cancer. Click here to learn more.

GO29537

A Phase III study of MPDL3280A (anti-PD-L1 antibody) in combination with Carboplatin + Nab-Paclitaxel in patients with non-squamous non small cell lung cancer [IMpower 130]. Click here to learn more.

GO29437

A Phase III study of MPDL3280A (Anti-PD-L1) in combination with Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel compared with Carboplatin + Nab-paclitaxel in patients with Stage IV squamous non small cell lung cancer (NSCLC) [IMpower 131]. Click here to learn more.

ABI-007-NSCL-006

Safety and efficacy study of Nab®-Paclitaxel with CC-486 and Nab®-Paclitaxel monotherapy as second-line treatment for advanced nonsquamous non small cell lung cancer. Click here to learn more.

G1T28-03

Study of G1T28 in patients with previously treated extensive stage SCLC receiving Topotecan chemotherapy. Click here to learn more.

ABI-007-NSCL-003

Safety and efficacy study of Abraxane as maintenance treatment after Abraxane Plus Carboplatin in first-line Stage IIIB / IV squamous cell non small cell lung cancer. Click here to learn more.

LUNGMAP

S1400 biomarker-targeted second-line therapy in treating patients with recurrent Stage IIIB-IV squamous cell lung cancer. Click here to learn more.

S0819

A randomized Phase III study comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel Avastin with or without concurrent Cetuximab in patients with advanced non small cell lung cancer.

JPBK

A randomized Phase III study of LY2835219 plus best supportive care versus erlotinib plus best supportive care in patients with Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy

ARCTIC:

A Phase III, open-label, randomized, multi-center, international study of MEDI4736 vs standard of care in patients with locally advanced or metastatic non small cell lung cancer (Stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements.

GO29527

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer. Click here to learn more. 

E4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK). Click here to learn more. 

ADAURA

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA). Click here to learn more. 

STARTRK2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Click here to learn more. 

CA209-384

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks. Click here to learn more. 

CA209-370

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370). Click here to learn more. 

MS200095-0022

A Phase II Single-arm Trial to Investigate Tepotinib in Stage IIIB/IV Adenocarcinoma of the Lung With MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-doublet-containing Regimen. Click here to learn more. 

MIRATI 265-109

Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor. Click here to learn more.

LUC2001

A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation). Click here to learn more.

eXALT3

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients. Click here to learn more.

UCBC